Intellia Therapeutics, Inc. (NTLA) on Monday reported positive topline results from its Phase 3 HAELO trial of lonvo-z, a CRISPR-based gene editing therapy for Hereditary angioedema (HAE). The study met its primary goal.
HAE is a rare genetic condition in which patients experience recurrent and potentially life-threatening swelling attacks in various parts of their body.
Results showed a one-time infusion of lonvo-z cut attack rates by 87% versus placebo over six months, with monthly attacks averaging 0.26 compared with 2.10 in the placebo group. The company said a significantly higher proportion of patients remained attack-free during the study period versus placebo.
Lonvo-z demonstrated a favorable safety profile, with all reported adverse events being mild to moderate.
Intellia said it has begun a rolling biologics license application submission with the U.S. Food and Drug Administration and expects a potential U.S. launch in the first half of 2027, if approved.
Shares rose more than 4% in pre-market trading after closing at $13.63 on Friday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.